Bone Biologics Corp
NASDAQ:BBLG
Bone Biologics Corp
Research & Development
Bone Biologics Corp
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bone Biologics Corp
NASDAQ:BBLG
|
Research & Development
-$1.9m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-8%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Bone Biologics Corp
Glance View
Bone Biologics Corp. operates as a medical device company, which engages in the research and development of bone regeneration in spinal fusion. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is also focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX medical device is a combination product which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The NELL-1/DBX Fusion Device offers a range of procedures including Spine Implants, Non-Union Trauma Cases and Osteoporosis. NELL-1 is a function specific recombinant human protein in laboratory bench models to recapitulate normal human growth and development to provide control over bone and cartilage regeneration. The platform technology is its human protein, known as NELL-1, a skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration.
See Also
What is Bone Biologics Corp's Research & Development?
Research & Development
-1.9m
USD
Based on the financial report for Sep 30, 2025, Bone Biologics Corp's Research & Development amounts to -1.9m USD.
What is Bone Biologics Corp's Research & Development growth rate?
Research & Development CAGR 10Y
-8%
Over the last year, the Research & Development growth was -55%. The average annual Research & Development growth rates for Bone Biologics Corp have been -30% over the past three years , -37% over the past five years , and -8% over the past ten years .
